Covid19 Clinical Trial - Usefulness of DORNASE in COVID-19 on HFNO

Status Terminated

Clinical Trial Summary

COVID-19 pneumonia manifests among others with a thick bronhial secretion. It contains an increased number of neutrophil extracellular traps (NETs), formed during netosis. DNA is a major component in NETs. DNAse alfa (Pulmozyme®, Roche) is a recombinant human enzyme, registered for inhalations in patients with Cystic fibrosis, in which NETs are also a typical characteristic. DNAse alfa inhalations are typically well tolerated and with no major side effects. Some initial reports exist of using DNAse alfa inhalations in COVID-19 patients, that had benefitial effects. There are some trials registered with ClinicalTrials, investigating the usufulness of DNAse alfa in intubated patients, but the investigators have no knowledge of a trial, investigating the usufulness of this drug in patients receiving High Flow Nasal Oxygen therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05139901
Study type	Interventional
Source	University Medical Centre Ljubljana
Contact
Status	Terminated
Phase	Phase 4
Start date	December 1, 2021
Completion date	February 22, 2023

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04901676` - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	Phase 3
Not yet recruiting	`NCT04534478` - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19	Phase 4
Active, not recruiting	`NCT05002517` - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab	Phase 3
Completed	`NCT05008393` - Efficacy of PJS-539 for Adult Patients With COVID-19.	Phase 2
Completed	`NCT04569877` - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia	Phase 2
Not yet recruiting	`NCT05286255` - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias	Phase 1
Completed	`NCT05035589` - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Completed	`NCT06113432` - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study	N/A
Recruiting	`NCT05042063` - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting	`NCT04615429` - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19	Phase 2
Completed	`NCT05047653` - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting	`NCT05047016` - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY	N/A
Active, not recruiting	`NCT05033847` - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above	Phase 2
Recruiting	`NCT06113757` - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease	N/A
Completed	`NCT05504655` - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting	`NCT05035524` - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19	N/A
Completed	`NCT05065879` - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes	Phase 4
Withdrawn	`NCT04390217` - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia	Phase 2
Withdrawn	`NCT04460105` - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia	Phase 1
Suspended	`NCT04901689` - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	Phase 3